

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
08 May 2025 (08.05.2025)



(10) International Publication Number
WO 2025/096903 A1

(51) International Patent Classification:
C07K 16/36 (2006.01) A61P 7/04 (2006.01)

(21) International Application Number:
PCT/US2024/054068

(22) International Filing Date:
01 November 2024 (01.11.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/547,019 02 November 2023 (02.11.2023) US

(71) Applicant: **BIOCRYST PHARMACEUTICALS, INC.**
[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC
27703 (US).

(72) Inventors: **BABU, Yarlagadda, S.**; 4836 Southlake Park-
way, Birmingham, AL 35244 (US). **CHEN, Xilin**; 1695
Ridge Haven Run, Alpharetta, GA 30022 (US). **WU,**
Mousheng; 1210 Buckhead Circle, Vestavia Hills, AL
35216 (US). **MA, Yuanyuan, X.**; 2628 Crossgate Lane,
Vestavia Hills, AL 35216 (US). **CHENG, Xiaogang**; 518
Twin Creek Road, Hoover, AL 35223 (US).

(74) Agent: **GORDON, Dana, M.** et al.; Foley Hoag LLP, 155
Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-C2 BINDING AGENTS AND CONJUGATES THEREOF

(57) Abstract: The present disclosure relates to, inter alia, compounds (e.g., antibodies or antigen binding fragments thereof, or conju-
gates thereof) that bind to complement protein 2 (C2), and the use of the compounds in methods for treating, or ameliorating one or
more symptoms of a disease or disorder associated with the complement pathway.

WO 2025/096903 A1